XCUR EXICURE, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1698530 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-97.7%
TTM net income YoY-235.0%
TTM EPS YoY65.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,228.2%
Net margin-801.4%
FCF margin—
EBITDA margin-1,222.6%
Returns
ROE-132.6%
ROA-34.0%
ROIC (approx.)-326.7%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets85.5%
Debt / equity0.00x
Current ratio0.71x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $174,000 | $312,000 | $655,000 | $888,000 | $935,000 | $808,000 | $0 | $0 |
| SG&A expense | $889,000 | $1.29M | $1.60M | $1.50M | $1.51M | $2.22M | $1.44M | $1.43M |
| Operating income | -$1.05M | -$1.64M | -$2.26M | -$2.39M | -$2.51M | $2.92M | -$7.59M | -$2.57M |
| Interest expense | — | — | $1,000 | $0 | — | — | $0 | $12,000 |
| Pretax income | -$1.12M | -$1.83M | -$3.53M | -$2.44M | -$2.62M | $3.01M | -$7.18M | -$1.08M |
| Income tax | $0 | $0 | -$634,000 | $0 | $0 | $0 | $0 | $8,000 |
| Net income | -$1.12M | -$1.83M | -$2.90M | -$2.44M | -$2.62M | $3.01M | -$7.18M | -$1.09M |
| EBITDA | -$1.01M | -$1.59M | -$2.23M | -$2.31M | -$2.44M | $2.98M | -$7.58M | -$2.56M |
| EPS (basic) | -0.18 | -0.29 | — | -0.39 | -0.41 | 0.49 | — | -0.57 |
| EPS (diluted) | -0.18 | -0.29 | — | -0.39 | -0.41 | 0.49 | — | -0.57 |
| Weighted avg. shares (diluted) | 6.37M | 6.37M | — | 6.32M | 6.32M | 6.18M | — | 1.90M |
| Balance sheet | ||||||||
| Cash & equivalents | $1.72M | $2.60M | $3.75M | $4.44M | $7.86M | $10.42M | $12.51M | $951,000 |
| Current assets | $2.32M | $3.53M | $4.62M | $5.44M | $8.65M | $11.30M | $13.67M | $2.60M |
| PP&E, net | $178,000 | $219,000 | $306,000 | $527,000 | $712,000 | $565,000 | $26,000 | $33,000 |
| Goodwill | $4.40M | $4.40M | $4.40M | $3.34M | $3.34M | $3.34M | $0 | — |
| Intangibles | $3.78M | $3.78M | $3.78M | $3.78M | $3.78M | $3.78M | $0 | — |
| Total assets | $11.40M | $12.76M | $14.04M | $15.27M | $18.74M | $20.68M | $15.06M | $10.63M |
| Current liabilities | $4.17M | $4.46M | $3.89M | $2.77M | $4.57M | $3.89M | $3.07M | $3.65M |
| Total liabilities | $10.42M | $10.66M | $10.12M | $8.34M | $9.88M | $9.30M | $8.28M | $9.09M |
| Shareholders' equity | $977,000 | $2.10M | $3.93M | $6.93M | $8.86M | $11.38M | $6.77M | $1.54M |
| Shares outstanding | 6.37M | 6.37M | 6.37M | 6.37M | 6.32M | 6.32M | 6.03M | 2.17M |
| Cash flow statement | ||||||||
| Operating cash flow | -$887,000 | -$1.14M | -$1.15M | -$3.53M | -$2.28M | -$1.60M | -$845,000 | -$449,000 |
| Capital expenditure | — | — | -$213,000 | -$106,000 | — | — | $0 | $0 |
| Free cash flow | — | — | -$934,000 | -$3.42M | — | — | -$845,000 | -$449,000 |
| Investing cash flow | $0 | $0 | $455,000 | $108,000 | -$280,000 | -$2.09M | $0 | $0 |
| Financing cash flow | $0 | $0 | $0 | $0 | $0 | $1.60M | $12.40M | $0 |
| Depreciation & amortization | $40,000 | $49,000 | $28,000 | $82,000 | $71,000 | $61,000 | $7,000 | $7,000 |
| Stock-based compensation | — | — | $1,000 | $0 | $1,000 | $0 | $6,000 | $5,000 |
Free plan shows the latest 8 periods; Pro shows all 42 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.